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Objective: A high monounsaturated fatty acid (MUFA) and polyunsaturated fatty acid (PUFA) intake is associated with lower
plasma low-density lipoprotein (LDL)-cholesterol. However, PUFA may increase the susceptibility of LDL to undergo oxidative
modifications. The aim of this study was to analyze the association of habitual dietary fat intake with LDL size and oxidizability.
Design: Cross-sectional.
Setting: Cohort study.
Subjects: Seven hundred and fifty-eight subjects with normal, impaired glucose metabolism and type II diabetes.
Interventions: Mean LDL size was measured by high-performance gel-filtration chromatography. In vitro oxidizability of LDL
was determined by measuring lag time, reflecting the resistance of LDL to copper-induced oxidation. Information about dietary
fat intake was obtained by a validated food frequency questionnaire.
Results: PUFA intake (energy percent) was significantly and negatively associated with LDL size in subjects with type II diabetes
(standardized beta (95% confidence interval) 0.17 (0.28;0.06)) and impaired glucose metabolism – although not
statistically significant – (0.09 (0.24;0.05)), but not in subjects with normal glucose metabolism (0.01 (0.10;0.12)) (P-value
for interaction¼0.02). No significant associations were observed for total, saturated fat and MUFA intake with LDL size. Intake of
fat was associated with lag time; however, the small magnitude of the associations suggested that the composition of dietary fat
is not a major factor affecting lag time. The same association with lag time was observed in all three glucose metabolism
categories.
Conclusions: In individuals with abnormal glucose metabolism, higher PUFA intake is associated with smaller LDL particle size,
but does not alter the susceptibility of LDL to in vitro oxidation.
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Introduction
Small, dense low-density lipoprotein (LDL) particles are
associated with a higher risk of atherosclerosis (Gardner
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et al., 1996; Lamarche et al., 1997). Oxidation of LDL is
considered to be the key event in the development of
atherosclerosis (Steinberg et al., 1989). Small, dense LDL is
more susceptible to oxidation (de Graaf et al., 1991; Chait
et al., 1993; Dejager et al., 1993). Subjects with impaired
glucose metabolism and type II diabetes have an adverse
lipid profile, including predominance of small, dense LDL
(Austin et al., 2000; Yoshino et al., 2002), and they have an
increased risk of atherosclerosis (Kannel and McGee, 1979;
de Vegt et al., 1999).
Previous research has demonstrated that there is a
relationship between dietary fat intake and the incidence
of atherosclerosis (Schaefer, 2002). Monounsaturated fatty
acid (MUFA) and polyunsaturated fatty acid (PUFA) intake
are associated with a decrease in plasma LDL-cholesterol
(Vega et al., 1982; Rivellese et al., 2003). However, PUFA may
increase the susceptibility of LDL to undergo oxidative
modifications (Scheffer et al., 2001; Kratz et al., 2002). It
has previously been found that dietary PUFA intake reduced
LDL size (Kratz et al., 2002). The aim of this study was to
investigate the association of fat intake with LDL size and
susceptibility to in vitro oxidation of LDL in a large
population cohort. In addition, we investigated whether
these possible associations were similar in subjects with
normal glucose metabolism, impaired glucose metabolism
and type II diabetes.
Subjects and methods
Study design and methods
The Hoorn study, a cohort study on glucose metabolism and
cardiovascular risk factors among a general population in the
Netherlands, started in 1989 with 2484 subjects aged 50–75
years at baseline (Mooy et al., 1995). In 2000–2001, a follow-
up examination was conducted in selected subjects, then
aged 60–87 years. We invited all surviving subjects with type
II diabetes (n¼176), and random samples of individuals with
normal glucose metabolism (n¼705) or impaired glucose
metabolism (n¼193) based on their glucose metabolism
status at the previous examination in 1996–1998 (de Vegt
et al., 2001). Of the 1074 individuals invited for the 2000–
2001 follow-up examination, 648 subjects participated
(60.3%). Among the reasons for not participating in the
follow-up examinations were lack of interest (30%), comor-
bidity (23%), high age (7%), unwillingness to travel (6%),
participation considered too time consuming (6%) and
miscellaneous reasons (15%). Thirteen percent were com-
plete non-responders. To increase the number of individuals
with type II diabetes, we also invited 217 individuals with
type II diabetes from the Hoorn Screening study aged
50–75 years, carried out in 1999, of which 182 participated
(Spijkerman et al., 2002). The Ethical Review Committee of
the VU University Medical Center approved the study. All
subjects gave their written informed consent before partici-
pation.
Anthropometric data were obtained from all subjects,
wearing light clothes only. Body mass index (BMI) was
calculated by dividing weight by height square. On their visit
to the research center, participants were asked to bring their
medication. Name and dosages of medications were recorded
and coded. Cardiovascular history and lifestyle habits,
including smoking, were assessed by questionnaire.
HaemoglobinA1c was analyzed by high-performance
liquid chromatography (reference range 4.3–6.1%). Fasting
plasma glucose concentration and 2-h post-load plasma
glucose concentration, total cholesterol, high-density lipo-
protein (HDL)-cholesterol and triglyceride were measured by
enzymatic methods (Roche, Mannheim, Germany). LDL-
cholesterol was directly determined by the N-geneous assay
(Genzyme, Cambridge, MA, USA). Insulin was determined
using a two-site immuno-radiometric test. Paired monoclo-
nal antibodies were used (Medgenix, Diagnostics, Fleurus,
Belgium).
LDL size and oxidizability
LDL was prepared by ultracentrifugation of ethylenediami-
netetraacetic acid (EDTA)-plasma densities between 1.019
and 1.063 kg/l. After isolation, LDL samples were kept under
nitrogen at 41C in the dark. The mean LDL size was measured
by high-performance gel-filtration chromatography as de-
scribed previously (Scheffer et al., 1997), with thyroglobulin
and fibrinogen as calibrators of known diameter. Intra-assay
and inter-assay coefficients of variation for the gel-filtration
chromatography method were 0.1 and 0.2%, respectively.
LDL samples were desalted by gel-filtration to remove
excess of EDTA using 5 ml HiTrap desalting columns
(Amersham Bio-sciences, Uppsala, Sweden), equilibrated
with 10 mmol/l phosphate-buffered saline (pH 7.4), contain-
ing 2.8 mmol/l EDTA. In vitro oxidizability of LDL was
determined by measuring the resistance of LDL to oxidation
and was expressed as lag time (Esterbauer et al., 1989).
Experiments were performed at 301C on a HTS7000 plate
reader (Perkin-Elmer, Norwalk, CT, USA). Copper (II)
ions were used as pro-oxidant at a final concentration of
18 mmol/l. The intra-assay and inter-assay coefficients of
variation for lag time determination were 1.6 and 3.6%,
respectively. All samples were assayed for LDL in vitro
oxidizability within 2 days of LDL isolation. The total
amount of conjugated dienes formed during in vitro oxida-
tion was calculated from the difference between the max-
imum and initial absorbance at 232 nm using 29 500 l/mol/
cm as molar extinction coefficient (Kleinveld et al., 1992).
Dietary intake
Information about dietary intake of the participants was
obtained by a validated food frequency questionnaire (Ocke
et al., 1997a, b), which was linked to an extended version of
the computerized Dutch Food composition table 1996
(Stichting NEVO, 1996). Total fat intake was split up in
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saturated fat intake, MUFA and PUFA intake. Fat intake was
defined as energy percentages ((fat (kcal) /total energy (kcal))
*100) to correct for total energy intake.
Statistical analysis
Three glucose metabolism categories were defined according
to the WHO99 criteria (Alberti and Zimmet, 1998). We
excluded people with missing data on primary variables of
interest (LDL size and lag time and conjugated diene
production n¼43, glucose metabolism n¼14 and food
questionnaire n¼16). We also excluded one individual with
extreme values of dietary intake (energy intake 450 000 kJ).
Thus, the study population consisted of 758 individuals, 281
subjects with normal glucose metabolism, 179 subjects
with impaired glucose metabolism and 298 subjects with
type II diabetes. Baseline characteristics are presented
as means with standard deviations (s.d.), but for insulin
and triglyceride concentrations (skewed data) the median
and interquartile ranges are shown. Univariate Pearson’s
correlations were calculated between explored variables and
outcomes. To test for linear trend in study sample character-
istics over categories of glucose metabolism, a linear
regression model was used with glucose metabolism category
as a linear explanatory variable. We tested for possible effect
modification by glucose metabolism or sex on the associa-
tion of fat intake with lag time and LDL size by calculating
the respective interaction terms. Linear regression models
were performed stratified for glucose metabolism with lag
time and LDL size as dependent variable and with indepen-
dent variables of interest (amount and type of dietary fat
defined as energy percentage), first adjusted for sex and age
(model 1), and subsequently for other macronutrients
(carbohydrates, protein) (model 2), triglycerides (model 3
LDL size), and vitamin E supplement use, LDL-cholesterol,
HDL-cholesterol, and triglycerides, LDL particle size, and
HbA1c (model 3 lag time). All associations of the regression
analyses are reported as standardized betas with 95%
confidence intervals. Statistical analyses were performed
with the Statistical Package for Social Sciences (SPSS) for
Windows version 10.1.
Results
Table 1 presents the characteristics and the dietary (fat)
intake of men and women stratified for glucose metabolism.
LDL size was smaller in men than in women (Po0.001). The
mean LDL size of subjects with type II diabetes was smaller
than in subjects with normal and impaired glucose metabo-
Table 1 Characteristics of men and women stratified by glucose metabolism status (n¼758)
Men Women
NGM IGM Diabetes NGM IGM Diabetes
N 136 92 152 145 87 146
Age (years) 69 (6) 70 (7) 67 (9) 68 (6) 71 (6) 69 (8)
LDL size (nm) 21.5 (0.3) 21.4 (0.4) 21.2 (0.5)* 21.8 (0.3) 21.6 (0.4) 21.4 (0.5)*
LDL lag time (min) 72.2 (9.8) 71.1 (9.1) 71.3 (9.1) 72.5 (9.5) 70.8 (9.4) 70.3 (9.8)
Conjugated diene production (mmol/g LDL protein) 609 (69) 600 (82) 609 (81) 624 (76) 602 (72) 601 (70)*
Fasting glucose (mmol/l) 5.47 (0.37) 6.07 (0.48) 7.77 (1.83)a 5.39 (0.38) 6.09 (0.48) 7.59 (1.65)a
Post-load glucose (mmol/l) 5.45 (1.17) 7.88 (1.89) 11.37 (3.12)a 5.76 (1.13) 8.13 (1.51) 11.93 (2.68)a
HbA1c (%) 5.7 (0.4) 5.8 (0.4) 6.6 (0.9) 5.7 (0.4) 5.9 (0.3) 6.6 (0.9)
Insulin (pmol/l)b 47 (37–63) 62 (45–78) 83 (52–119)* 45 (35–56) 75 (55–93.75) 87 (61–113)*
Total cholesterol (mmol/l) 5.4 (1.0) 5.5 (1.0) 5.2 (1.0) 6.2 (0.9) 6.0 (1.0) 5.9 (1.0)
HDL-cholesterol (mmol/l) 1.30 (0.35) 1.27 (0.32) 1.14 (0.3) 1.70 (0.40) 1.59 (0.42) 1.36 (0.35)*
LDL-cholesterol (mmol/l) 3.5 (0.8) 3.7 (0.9) 3.4 (0.9) 3.9 (0.9) 3.8 (0.9) 3.7 (0.9)
Triglycerides (mmol/l)b 1.3 (0.9–1.6) 1.3 (1.0–1.7) 1.5 (1.1–2.2)* 1.1 (0.8–1.5) 1.3 (1.0–1.7) 1.6 (1.2–2.3)*
Body mass index (kg/m2) 26.2 (3.3) 27.2 (3.2) 28.6 (3.5)* 26.0 (3.3) 28.6 (4.8) 29.5 (5.2)*
Smoking (%) 20 22 14 11 14 11
Lipid-lowering drugs (%) 15 15 23 12 17 18
Energy (kJ) 9081 (2010) 8786 (2036) 9111 (2606)* 7502 (2336) 7048 (1759) 7138 (2038)
Carbohydrate (energy percent) 45.6 (6.2) 42.9 (6.7) 43.2 (6.7)* 46.2 (6.4) 47.2 (7.5) 46.7 (6.4)
Protein (energy percent) 14.7 (2.3) 14.6 (1.7) 15.5 (2.4) 15.5 (2.7) 15.8 (2.5) 16.1 (2.6)
Total fat (energy percent) 34.5 (5.6) 36.1 (6.1) 35.2 (5.2) 34.4 (5.4) 33.0 (6.2) 35.0 (5.5)
Saturated fat (energy percent) 14.6 (2.8) 15.1 (2.9) 14.4 (2.4) 14.9 (3.0) 14.2 (2.8) 14.9 (2.9)
MUFA (energy percent) 12.9 (2.5) 14.0 (3.0) 13.5 (2.4) 13.1 (2.6) 12.4 (2.8) 13.0 (2.6)
PUFA (energy percent) 6.6 (2.5) 6.7 (2.5) 7.0 (2.0)* 6.0 (1.8) 6.2 (1.8) 6.7 (2.2)*
Vitamin E (%) 6.6 5.4 3.3 4.1 5.7 3.4
Multivitamin (%) 11.8 5.4 8.6 17.2 10.3 12.3
Abbreviations: IGM, impaired glucose metabolism; MUFA, monounsaturated fat; NGM, normal glucose metabolism; PUFA, polyunsaturated fat.
*P for trend (age-adjusted) o0.05.
aPo0.05 by definition.
bBaseline characteristics are presented as means with s.d.’s, but for insulin and triglyceride concentrations (skewed data) the median and interquartile ranges are
shown.
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lism (Po0.001 for both men and women). No significant
differences were observed in lag time between men and
women, nor between glucose metabolism categories. The
mean energy intake was lower in women than in men
(Po0.001). There was no significant difference in type of fat
intake between men and women and between the three
categories of glucose metabolism.
In Table 2, univariate Pearson’s correlations are shown
between dietary fat intake and outcome variables. Weak
correlations were shown between total fat, saturated fat and
MUFA with LDL size, lag time and conjugated diene
production. There was a strong negative correlation between
PUFA and LDL size, and a strong positive correlation
between PUFA and conjugated dienes.
Men and women were pooled in the linear regression
analyses, because the relation between dietary fat and LDL
size or lag time was not modified by sex (P40.10). Table 3
shows the linear regression analyses of the total population
for LDL size as dependent variable, adjusted for age and sex.
After stratification for glucose metabolism status, a signifi-
cant negative association was observed for PUFA intake and
LDL size in subjects with type II diabetes. This association
was less strong in subjects with impaired and absent in
subjects with normal glucose metabolism (Table 3) (P for
interaction¼0.02). The association between PUFA intake
and LDL size was not explained by carbohydrate and protein
intake. Adjustment for triglyceride did not alter the results.
There were no significant associations between total fat,
saturated fat, MUFA intake and LDL size.
Intake of total fat, saturated fat and MUFA was negatively
associated with lag time with standardized betas of 0.07
(0.14; 0.0002), 0.07 (0.14; 0.0002) and 0.07 (0.14;
0.0027), respectively. The associations remained but lost
significance after adjustment for carbohydrate and protein
intake. Adjustment for vitamin E, the serum concentrations
of LDL-cholesterol, HDL-cholesterol, and triglycerides, LDL
particle size, and glycemic control further attenuated these
associations with standardized betas of 0.02 (0.11; 0.07)
for total fat, 0.02 (0.10; 0.06) for saturated fat and 0.03
(0.12; 0.06) for MUFA. No significant differences between
glucose metabolism categories were observed in associations
Table 2 Pearson’s correlations of dietary fat intake with LDL size, lag
time and conjugated dienes
LDL size
(nm)
Lag time
(min)
Conjugated
dienes (mmol/g)
Total fat (energy %) 0.081 0.070 0.032
Saturated fat (energy %) 0.033 0.067 0.092
MUFA (energy %) 0.077 0.074 0.000
PUFA (energy %) 0.165 0.001 0.210
Abbreviations: LDL, low-density lipoprotein; MUFA, monounsaturated fat;
PUFA, polyunsaturated fat.
Table 3 Age- and sex-adjusted associations of dietary fat intake with LDL size stratified for glucose metabolism status
NGM (n¼281) IGM (n¼179) Diabetes (n¼298) Overall
Standardized beta (95% CI)
Total fat (energy percent)
Model 1 0.04 (0.15; 0.06) 0.04; (0.11 0.19) 0.09 (0.20; 0.02) 0.06 (0.12; 0.01)
Model 2 0.01 (0.12; 0.15) 0.02; (0.17 0.20) 0.01 (0.16; 0.13) 0.01 (0.10; 0.08)
Model 3 0.04 (0.13; 0.05) 0.02; (0.10 0.15) 0.05 (0.13; 0.03) 0.03 (0.08; 0.02)
Saturated fat (energy percent)
Model 1 0.05 (0.15; 0.06) 0.13 (0.01; 0.28) 0.00 (0.11; 0.11) 0.02 (0.05; 0.09)
Model 2 0.00 (0.13; 0.12) 0.14 (0.02; 0.30) 0.08 (0.04; 0.21) 0.08 (0.00; 0.15)
Model 3 0.05 (0.14; 0.04) 0.13 (0.01; 0.24) 0.01 (0.07; 0.10) 0.03 (0.03; 0.08)
MUFA (energy percent)
Model 1 0.05 (0.16; 0.06) 0.01 (0.14; 0.16) 0.06 (0.17; 0.05) 0.04 (0.11; 0.03)
Model 2 0.01 (0.13; 0.15) 0.02 (0.21; 0.16) 0.05 (0.10; 0.20) 0.02 (0.07; 0.11)
Model 3 0.06 (0.14; 0.03) 0.01 (0.12; 0.13) 0.01 (0.09; 0.07) 0.01 (0.07; 0.04)
PUFA (energy percent)
Model 1 0.02 (0.10; 0.14) 0.09 (0.24; 0.05) 0.17 (0.28; 0.06) 0.13 (0.20; 0.06)
Model 2 0.03 (0.10; 0.15) 0.11 (0.26; 0.04) 0.14 (0.26; 0.03) 0.12 (0.19; 0.05)
Model 3 0.04 (0.06; 0.14) 0.11 (0.23; 0.00) 0.13 (0.21; 0.05) 0.09 (0.14; 0.04)
Abbreviations: IGM, impaired glucose metabolism; MUFA, monounsaturated fat; NGM, normal glucose metabolism; PUFA, polyunsaturated fat.
Model 1¼Age and sex adjusted.
Model 2¼Model 1þ carbohydrate and protein intake.
Model 3¼Model 1þ triglyceride.
A standardized beta of –0.17 indicates that if the independent variable (PUFA intake) decreases 1 s.d., the dependent variable (LDL size) increases 0.17 s.d. This
corresponds with a of beta of –0.04, indicating that if PUFA intake increases with 1 energy percent, LDL size decreases with 0.04 nm in subjects with type II diabetes.
A standardized beta of –0.13 corresponds with a of beta of –0.03, indicating that if PUFA intake decreases with 1 energy percent, LDL size increases with 0.03 nm.
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of fat intake with lag time (data not shown). Saturated fat
was negatively, and PUFA was positively associated with the
total amount of conjugated dienes formed during oxidation
of LDL (0.09 (0.17; 0.02) and 0.22 (0.15; 0.29),
respectively), and these associations were independent of
carbohydrate and protein intake (data not shown).
All associations are presented as standardized betas. For
example, a standardized beta of 0.12 indicates that if the
independent variable (PUFA intake) increases 1 s.d., the
dependent variable (LDL size) decreases 0.12 s.d.
Discussion
In this study, we observed that habitual dietary PUFA intake
was significantly and negatively associated with LDL size in
subjects with type II diabetes, but less strong in subjects with
impaired and not at all in subjects with normal glucose
metabolism, indicating that the relationship between PUFA
and LDL size is modified by glucose metabolism status. There
was no association of PUFA intake with lag time.
We used the automated gel-filtration chromatography
method because of good reproducibility, high precision
and the possibility to analyze large series of samples. We
used in vitro measures for LDL oxidizability, because lag time
has been found to be inversely related to progression of
coronary atherosclerosis (Regnstrom et al., 1992). The
suitability of in vitro susceptibility to oxidation may be
questioned, as we recently observed that this measure does
not correlate with in vivo LDL oxidation (Scheffer et al.,
2003).
The reproducibility and validity of the food frequency
questionnaire has been evaluated previously, and was
generally good (Ocke et al., 1997). The energy percentages
for the different types of fat were higher than recommended
by the WHO dietary recommendations for the prevention of
chronic disease (Shikany and White, 2000).
The food frequency questionnaire that was used has
limitations in capturing energy intake (Schatzkin et al.,
2003). The Observing Protein and Energy Nutrition data
indicate that a true relative risk between absolute intakes of
dietary factors with disease would be attenuated. This
attenuation is lessened in analyses of energy-adjusted
factors, which were reported in our study. Nevertheless, if
this limitation is applicable to beta’s also, it could be that the
associations between habitual dietary fat intake and LDL size
and oxidizability were underestimated. So the interpretation
of these findings should be with caution.
To our knowledge, this is the first population cohort study
to assess the association between habitual dietary fat intake
and lag time and LDL size in subjects with normal and
impaired glucose metabolism, and type II diabetes. The
design was such that we over sampled subjects with impaired
glucose metabolism and type II diabetes, to enhance the
power of the study. The associations we found were weaker
than anticipated. This may be explained by several factors.
Firstly, the people who know that they have type II diabetes
may have changed to a healthier diet. However, there was no
difference in dietary fat intake between the three glucose
metabolism categories. Importantly, the majority of the
diabetic subjects was newly detected, and they were unaware
of their diabetic state when they filled in the food frequency
questionnaire. Secondly, subjects with a high BMI usually
underestimate their total energy intake compared to subjects
with low BMI (Braam et al., 1998). As subjects with type II
diabetes more frequently have a high BMI than subjects with
normal glucose metabolism, we adjusted for this difference
and we used energy percentages of the different types of
dietary fat. When we analyzed the absolute dietary fat intake
(g/day), this did not show associations with lag time and LDL
size (data not shown).
The associations between dietary fat and LDL size have
previously been investigated in different populations. Lower
total fat intake was associated with smaller LDL size in
healthy non-smoking men (Dreon et al., 1998). Kratz
et al.(2002) concluded that dietary MUFA and PUFA had a
similar effect on LDL size in 56 healthy students (men and
women). They demonstrated that an LDL size reduction
occurred when replacing saturated fat by unsaturated fat,
which was in line with our findings. Several studies reported
that a high saturated fat intake was associated with a higher
proportion of larger and less atherogenic LDL particles and
with LDL size, but with a concomitant increase of the LDL-
cholesterol concentration (Campos et al., 1995; Dreon et al.,
1998). Rivellese et al. (2003) observed no effect of dietary
saturated fat, MUFA and n-3 fatty acids on LDL size in 162
healthy subjects.
It has been suggested that the possible association between
LDL size and dietary fat may be explained by plasma
triglyceride, the strongest determinant of LDL size (Dreon
et al., 1999). Insulin-resistant subjects, such as people with
impaired glucose metabolism and type II diabetes are
exposed to a longer post-prandial triglyceride excursion
(Heine and Dekker, 2002). This might explain why LDL size
could be more influenced by dietary fat in subjects with type
II diabetes and impaired glucose metabolism than in subjects
with normal glucose metabolism.
In our study, we observed a positive association between
habitual intake of carbohydrate and LDL size. This is not in
line with Siri and Krauss, 2005, who recently showed that
increased carbohydrates, through increasing plasma trigly-
ceride, are associated with a decline in LDL diameter.
However, it must be emphasized that these results are based
on a cross-sectional study design, rather than a dietary fatty
acid intervention. It could be that these relationships are not
strong enough to detect in a population study with normal
ranges of habitual fat and carbohydrate intake.
Fatty acids have been demonstrated before to be the main
determinants of LDL oxidation in a diabetic population
(Scheffer et al., 2001). Several studies have reported the
relation between dietary monounsaturated fat intake and
resistance of LDL to oxidation (Reaven et al., 1991; Abbey
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et al., 1993). The main picture that emerges from these
studies is that diets rich in PUFA result in LDL that are more
readily oxidized than LDL isolated form subjects who
consume diets rich in MUFA. Dietary saturated fat adversely
affect plasma lipids as well as susceptibility of LDL to
oxidation. However, this was not observed in our study
and a recent study reported that replacing saturated fat by
MUFA and PUFA in low fat diets did not affect LDL oxidative
susceptibility as measured by lag time (Yu-Poth et al., 2000).
Thus, the interaction of dietary fat with LDL composition
and oxidizability is still poorly understood (Kratz et al.,
2002). The lack of effect of dietary MUFA on lag time might
be put into the right context considering the major food
sources of fatty acids in this cohort. Milk/dairy products,
meat and meat products, grain and grain products and
sauces contribute to fat intake in the Netherlands (Hulshof
et al., 2004). In such populations that consume little
amounts of MUFA-rich oils or fats, intakes of MUFA are
highly correlated with intakes of saturated fat because meat
and meat products are relevant sources of dietary MUFA.
In the present study, we could not confirm beneficial
effects of habitual MUFA intake. We observed that higher
PUFA intake was associated with small LDL size and higher
conjugated diene production. In the study by Scheffer et al.
(2001), linoleic acid and oleic acid were major determinants
of the amount of conjugated dienes during LDL oxidation,
whereas fatty acids with three or more double bonds were
negatively associated with LDL lag time. Further studies may
investigate the association of the intake of individual PUFA
with LDL size and oxidizability.
In conclusion, in this cross-sectional study in 758 elderly
subjects, in subjects with abnormal glucose metabolism, a
higher habitual PUFA intake is associated with smaller LDL
size but not with lag time. Considering the major differences
in metabolic effects, the type of PUFA, and n-3 versus n-6,
need to be taken into account in future studies.
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